Narcolepsy: economic evaluations of treatments remain incomplete

How can you estimate a treatment’s value if the model represents only part of the disease? A systematic review of seven economic evaluations of narcolepsy treatments identifies important omissions. It questions the robustness of these decision-support tools, without establishing that any treatment is ineffective or too costly.

Diagram of the dimensions examined in economic evaluations of narcolepsy treatments: symptoms, quality of life and costs.
SleepEditorial illustration, not study data.

Seven economic models under scrutiny

The authors searched for economic evaluations of treatments for adults with type 1 or type 2 narcolepsy. Their bibliographic database search covered publications through May 2026, with an additional search of assessment agency websites through June or July 2026.

The seven included evaluations were all cost–utility models, which weigh costs against health benefits while accounting for quality of life. Their methodological quality was assessed using the Philips checklist.

These models shared a similar structure: an initial phase determined treatment response, followed by longer-term modelling that projected outcomes based on response status. Benefits were therefore extrapolated beyond the trials’ follow-up periods.

A representation focused on sleepiness

Treatment benefits were primarily represented by changes in excessive daytime sleepiness. Other symptoms were omitted. This restriction limits the models’ ability to represent the full consequences of narcolepsy and its treatment.

Efficacy comparisons frequently relied on expert opinion or individual trials rather than a systematic statistical synthesis of the evidence. This weakens economic comparisons between options, without allowing any conclusion here about which would be preferable.

Quality-of-life estimates were also problematic: they used conversions derived from populations without narcolepsy, different measures for different treatments, or unclear sources.

Costs and uncertainties only partly represented

Healthcare costs focused largely on drug acquisition. Indirect costs were rarely included, and downstream clinical and societal consequences were not directly modelled. Such a restricted estimate therefore does not necessarily capture a treatment’s full value.

Sensitivity analyses mainly explored parameter uncertainty. Validation and transparency varied considerably across models. The authors call for closer examination of uncertainties relating to methods and the structure of the evaluations themselves.

This work identifies missing data but does not provide a new economic comparison of treatments. To improve decision-making, the authors call in particular for quality-of-life measures derived from people with narcolepsy and more rigorous efficacy comparisons.

Limitations to keep in mind

This news article is based solely on the supplied PubMed abstract, without consultation of the full text. Detailed results for each model, funding and conflicts of interest have not been verified. The review concerns economic evaluations in adults, not a new assessment of treatments’ clinical efficacy.

What we can take away

These economic evaluations shed light on part of the problem, not the whole of narcolepsy. Their limitations demonstrate neither a lack of treatment benefit nor cost-effectiveness: they make these conclusions more uncertain.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.